Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$2.24

+$0.05 · +2.28%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

Company profile

Company website

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Kelvin Cooper
Listed since: Apr 23, 2026
Employees: 5

Market position

Volume: 70.56K; 0.06× average
Average volume: 1.22M; Average daily volume
Market cap: 3.92M USD
Beta: -4.76; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -0.47×
P/B (TTM): 0.73×
P/S (TTM): 0×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%

Financial health

Debt / equity: 0.02×

LABT news

defenseworld.netJul 30, 2026

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the…

Read source

prnewswire.comJul 22, 2026

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high…

Read source

defenseworld.netJul 17, 2026

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey

MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare the two businesses…

Read source

prnewswire.comJul 15, 2026

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects. SARASOTA, Fla.

Read source

prnewswire.comJul 7, 2026

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

Company highlights its differentiated Bisphosphocin ® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development SARASOTA, Fla., July 7,…

Read source

prnewswire.comJun 25, 2026

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.

Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program SARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the…

Read source